Daptomycin in the Treatment of Diabetic Foot Infections without Osteomyelitis; A Multicenter Study

Basit Öğe Kaydı
dc.authoridkomur, suheyla/0000-0003-2414-559X
dc.authoridUysal, Serhat/0000-0002-4294-5999
dc.contributor.authorIsikgoz Tasbakan, Meltem
dc.contributor.authorUysal, Serhat
dc.contributor.authorKomur, Suheyla
dc.contributor.authorKaragoz, Gul
dc.contributor.authorYapar, Nur
dc.contributor.authorOzturk, Anil Murat
dc.contributor.authorSipahi, Oguz Resat
dc.date.accessioned2025-01-27T20:22:33Z
dc.date.available2025-01-27T20:22:33Z
dc.date.issued2017
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Although diabetic foot infections are polymicrobial, gram-positive microorganisms comprise the majority. Daptomycin is a novel agent in treating infections due to multidrug-resistant gram-positive pathogens. In this multicenter study, the outcomes of the daptomycin treatment were evaluated retrospectively in the treatment of diabetic foot infectious without osteomyelitis. Materials and Methods: Patients with diabetic foot infection without osteomyelitis and who received daptomycin treatment were included into the study. Sociodemographic characteristics of the patients, risk factors for methicillin resistant Staphylococcus aureus (MRSA), antimicrobial treatment, and the data of microbiological and clinical outcomes of the cases were registered in a standard form by eleven centers. Clinical success was defined as a combination of end-of-treatment laboratory parameters, clinical and microbiological responses. Results: A total of 46 patients (30 males, 16 females) were clinically evaluated for the outcome of daptomycin therapy. Mean age was 61.09 +/- 11.82 years (31-81) and mean diabetes duration was 13 +/- 8.2 years. The number of mild, moderate and severe infections identified according to the infection scoring system of the Infectious Diseases Society of America (IDSA) were 12 (26.1%0), 25 (54.3%), and 9 (19.6%) respectively. Duration of daptomycin therapy was 17.5 +/- 9.3 days and overall daptomycin success rate was 82.6% (n= 38). Two patients developed side effects. Conclusion: The clinical success rate of this study which assessed the efficacy of daptomycin in diabetic foot infections was 82.6%. Daptomycin can be safely used even in severe cases having had no success with previous antibiotic therapy.
dc.identifier.doi10.5578/flora.66267
dc.identifier.endpage152
dc.identifier.issn1300-932X
dc.identifier.issue4
dc.identifier.startpage148
dc.identifier.urihttps://doi.org/10.5578/flora.66267
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21941
dc.identifier.volume22
dc.identifier.wosWOS:000458959600002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isotr
dc.publisherBilimsel Tip Yayinevi
dc.relation.ispartofFlora Infeksiyon Hastaliklari Ve Klinik Mikrobiyoloji Dergisi
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectDiabetic foot
dc.subjectDaptomycin
dc.subjectStaphylococcus aureus
dc.titleDaptomycin in the Treatment of Diabetic Foot Infections without Osteomyelitis; A Multicenter Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu